Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$6.32 USD

6.32
411,588

+0.09 (1.44%)

Updated Sep 19, 2024 03:59 PM ET

After-Market: $6.30 -0.02 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for VYGR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Voyager Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 231 119 133 181 282
Receivables 83 0 1 8 19
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 5 5 3 9 5
Total Current Assets 320 125 137 198 305
Net Property & Equipment 16 18 22 25 18
Investments & Advances 0 0 0 0 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 2 2 2 2 2
Total Assets 351 159 194 262 355
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 2 3 1 1 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 17 8 11 14 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 46 62 39 12 50
Total Current Liabilities 65 73 51 27 76
Mortgages 0 0 0 0 0
Deferred Taxes/Income 32 6 8 36 147
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 18 21 40 44 32
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 115 100 99 107 255
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 498 453 442 430 412
Retained Earnings -261 -394 -347 -276 -313
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 236 59 95 154 100
Total Liabilities & Shareholder's Equity 351 159 194 262 355
Total Common Equity 236 59 95 154 100
Shares Outstanding 44.00 38.60 37.90 37.40 37.00
Book Value Per Share 5.37 1.53 2.51 4.13 2.69

Fiscal Year End for Voyager Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 371 400 231 253 273
Receivables 3 3 83 3 3
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 6 5 6 6
Total Current Assets 382 409 320 262 282
Net Property & Equipment 16 17 16 17 17
Investments & Advances 0 1 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 3 3 2 2 2
Total Assets 436 470 351 295 316
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 8 2 3 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 10 8 17 11 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 27 57 46 47 35
Total Current Liabilities 40 73 65 62 45
Mortgages 0 0 0 0 0
Deferred Taxes/Income 19 13 32 38 51
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 41 18 19 20
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 101 129 115 118 117
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 619 614 498 494 491
Retained Earnings -283 -273 -261 -318 -292
Other Equity -1 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 335 341 236 176 199
Total Liabilities & Shareholder's Equity 436 470 351 295 316
Total Common Equity 335 341 236 176 199
Shares Outstanding 54.30 54.30 44.00 44.00 43.90
Book Value Per Share 6.18 6.28 5.37 4.01 4.53